

FRENCH DELEGATION

FRENCH HEALTHCARE DAYS


October 6 – 10, 2025



France, a global leader in Medical Biotechnology

France stands as one of world's leading nations in the field of medical biotechnology.

With a dynamic ecosystem built around competitiveness clusters, innovative hubs, world-class university hospitals, France continues to attract talent, investors, and international partnerships.

Home to over 800 biotech companies operating in the health sector, France is widely recognized for its capacity to innovate in key areas such as immunotherapy, gene and cell therapy, vaccines, rare diseases, and personalized medicine.

This ecosystem is supported by world-renowned academic research institutions, in close collaboration with universities and medical centers.

The French biotech industry is also highly internationally oriented. French companies export their expertise worldwide, actively participate in major global conventions, and collaborate with foreign partners to accelerate the development and delivery of innovative health solutions

Innovation



Dynamic



International



**BIOTECH
& PHARMA**

affilogic

**BiPER
Therapeutics**

covalab
R&D in Biotechnology

lovaltech
Beyond Immunization

NanoMedSyn

SUPERBRANCHE
MULTI-SCALE COLLABORATION

PRIOTHERA

VECT-HORUS
BREAKING BARRIERS

**CRO & CDMO
& SERVICES**

ALP

Banok

UNITHER
PHARMACEUTICALS

**GROUPE
ICARE**

NETRI

sounduct

**institut
Curie**

**INSTITUT
pasteur**

LYONBIOPOLE
AUVERGNE-RHÔNE-ALPES
THE HEALTH INNOVATION NETWORK

**INSTITUTE
& OTHERS**

FRENCH DELEGATION

Business France is proud to present a delegation of 18 French companies, showcasing the country's expertise and innovation in medical biotechnology and life sciences.

With a strong interest in the Japanese market, these companies are actively seeking business opportunities and strategic partnerships.





Combining Nanofitins® to design ideal targeted therapies

Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.

Each Nanofitin® is 20 times smaller than an antibody and hyperstable. Nanofitins® are easily combined by simple, rapid and proven methods to design an ideal targeted molecule.

Affilogic is investing internally in 4 programs which leverage the core advantages of the Nanofitins®:

- 1 – Bus2Brain : Enhanced brain uptake of biologics to reignite CNS therapies
- 2 – Respitide : Inhaled antiviral Nanofitin® therapeutics against respiratory infections
- 3 – GI Job : Targeting GI tract diseases by oral administration
- 4 – ODC : Small size Nanofitin®-Drug-Conjugates against solid tumours with a new therapeutic window

Moreover, with NanoVector, Affilogic is partnering with third parties to deliver their therapeutic compounds to specific cell/organs (ASO, siRNA, nanoparticles, antibodies, enzymes, peptides, CAR-T, AAV...).

Such programs illustrate the versatility of our Nanofitins®, designed as API or as vectors for specific transport of therapeutic molecule, systemically administrable but also via oral route for a local effect in the GI tract or via direct pulmonary delivery.

Targets: Big pharma, mid-size biotech, small biotech with fundings



<https://www.affilogic.com/>

Olivier KITTEN
CEO

olivier@affilogic.com

Affilogic is investing in 4 programs leveraging the core advantages of the Nanofitins®:



Enhanced brain uptake of biologics



Targeting GI tract diseases by oral administration



Inhaled antiviral therapeutics against respiratory infections



Small size Drug Conjugates against solid tumors with new therapeutic window



Moreover, Affilogic is partnering with third parties to deliver their therapeutic compounds to specific cell/organs (ASO, siRNA, nanoparticles, antibodies, enzymes, peptides, CAR-T, AAV...).






BiPER
Therapeutics

BiPER Therapeutics opens a new therapeutic pathway in the treatment of cancer.


Our first clinical candidate BPR001-615 is a first-in-class oral small molecule to treat gastro-intestinal tumors by pushing cancers cells to burn out. BPR001 inhibits BiP, a key protein involved in cancer cells survival and associated with very poor prognosis of patients when overexpressed in tumors and in plasma of patients. BPR001-615 has been developed to treat the 50% of BIP+ patients through precision medicine approach based on overexpression level of BiP in plasma of patients. BPR001-615 has been developed as an oral drug in monotherapy or in combination with standards of care to improve patient outcomes. In preclinical studies, patent-protected data demonstrate that BPR001 is effective in monotherapy outperforming standards of care and enhances a wide range of standard of care agents like chemotherapies, targeted therapies and immunotherapies. We aim at quickly expand worldwide to develop the company and propose investors to join us in this fantastic journey, create value together and bring our unique therapeutic solutions to patients.

Targets: investors and pharmaceutical companies



Mehdi CHELBI
CEO

mehdi.chelbi@biper-tx.com



<https://biper-tx.com/>



Founded in 1995, **Covalab** is a French biotechnology company renowned for its expertise in antibody engineering. With over three decades of experience, Covalab specializes in the design and development of a wide range of antibodies, including polyclonal, monoclonal, scFv, FAb, VHH, and recombinant antibodies, utilizing advanced techniques such as DNA immunization.

The company offers a fully integrated platform for antibody generation, with customizable services tailored to specific research, diagnostic, and therapeutic needs. Its expertise spans diverse fields including cancer research, neuroscience, and autoimmune diseases.

Covalab's comprehensive approach includes a careful immunogen and animal host selection, rigorous screening processes, and state-of-the-art characterization. Committed to quality, the company holds ISO 9001:2015 certification, reflecting its dedication to excellence in services, products, and R&D.

Targets: distributor of R&D products in biology, academic biology laboratories, biotechnology clusters



25 Years



15,000
Products



All inclusive
Services




Scientific
Team



<https://www.covalab.com/>

Meddy EL ALAOU
CSO

meddy.elalaoui@covalab.com



CUSTOM ANTIBODY

CATALOGUE PRODUCT



Lovaltech is a French biotech company pioneering next-generation nasal vaccines for infectious diseases. Spun out from cutting-edge academic research at INRAE and the University of Tours, Lovaltech develops needle-free vaccine solutions with enhanced mucosal immunity, better protection at the entry site of pathogens, and potential for both prevention and therapy.

LVT-001 is a novel nasal COVID-19 vaccine targeting current and future variants. Designed to induce strong mucosal and systemic immune responses, LVT-001 has demonstrated a broad protection across variants, Sterilizing immunity and safe and scalable production using fusion proteins and GRAS-grade excipients. We launched our first-in-human clinical trials with regulatory engagement underway via the European Medicines Agency (EMA).

And we are already developing the next vaccine candidates against Covid-Long, Influenza and Malaria.

Finally, we set-up a tech platform of Modular Muco-Excipient (ME) Platform: A Breakthrough Innovation for Nasal Vaccination.

Targets: biotech or pharma / immunology

**Beyond immunization,
Nasal vaccines for complete protection
Against infectious diseases and contagiousness**

Patrick BARILLOT
President

patrick.barillot@lovaltechnology.com



<https://www.lovaltechnology.com/>



NanoMedSyn has a breakthrough technology platform of proprietary ligands. These ligands, named AMFA (for Analogues of Mannose 6-phosphate Functionalized on Aglycone position), bind to a cell membrane receptor, the mannose 6-phosphate receptor (M6PR). This ubiquitous receptor is a key receptor for cell uptake leading to endo-lysosomal delivery. Our studies demonstrated that AMFA conjugation on therapeutic agents enhances both cell uptake and efficacy.

Applications. The ligands have been conjugated to enzymes, nanoparticles or antibodies. AMFA-grafting to enzymes is particularly appropriate for lysosomal storage disorders, where an enzyme is deficient in lysosome. For nanoparticles, the ligands are attractive to target several organs including prostate and muscles. Onto therapeutic antibodies, AMFA gives a new degradative function (see Figure). At first, the antibody-AMFA binds to its antigen (1). Then, AMFA recognizes M6PR (2), which promotes the cell uptake (3). In acidic endosomes, the antigen is dissociated from the antibody-AMFA (4). The antigen will be then degraded in lysosomes (5) whereas the antibody-AMFA is recycled out of the cell (6). By this way, the antibody-AMFA can perform multiple cycles of antigen degradation.

The business model of NanoMedSyn is to develop its delivery platform of therapeutics through research collaborations and licensing agreements with pharmaceutical and biotech partners.

Targets: Pharmaceutical groups or clinical-stage companies for long-term collaborations



<http://nanomedsyn.com/>

Marie MAYNADIER
General Manager

m.maynadier@nanomedsyn.com




By click-chemistry, our ligands can be conjugated to a wide range of therapeutic agents.

Enzyme-AMFA




Nanoparticle-AMFA



Antibody-AMFA



Antibody conjugated with AMFA performs antigen degradation





Priothera is committed to pioneering innovative therapies that can enhance the curative potential of both allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T cell therapy. Our goal is to deliver treatments that not only improve survival rates but also ensure safer and more effective long-term outcomes compared to today's standard care.

Priothera is exploring ways to address unmet medical needs in hematological malignancies by investigating innovative immune modulators that can enhance outcomes in allogeneic hematopoietic cell transplantation. Through the development of our investigational drug, mocravimod, we aim to address critical challenges in current allo-HCT maintenance strategies by enhancing the graft-versus-leukemia (GvL) effect while simultaneously reducing graft-versus-host disease (GvHD).

Targets: pharma

Priothera, Adding Quality Years to Life



<https://www.priothera.com/>

Philippe LIEVRE
Founder & CBO

philippe.lievre@priothera.com



WHY IT MATTERS

In the past decades very little progress has been made to improve relapse rates and quality of life after allo-HCT.

HOW IT WORKS


1) Grafted allo-T cells (a type of immune cells that kill other cells) migrate into lymphoid organs.

2) Priothera's investigational drug, Mocravimod, prevents allo-T cells from leaving the lymphoid organs, and therefore accumulate in lymph nodes and bone marrow.

3) The accumulation of allo-T cells results in enhanced killing of resident cancer cells (GvL) that escaped conditioning. This translates into reduced relapse rates.

4) Because fewer allo-T cells are released into the circulation, healthy tissue is spared from immune attack (GvHD). Consequentially GvHD is reduced.

Lymph Nodes & Bone Marrow





Superbranche is a French biotechnology start-up specializing in the development of iron oxide nanoparticles with a dendrimeric coating for advanced clinical applications as cell (immuno)therapy tracers.

Using cutting-edge proprietary processes, Superbranche achieves the reproducible synthesis of superparamagnetic particles with a uniform diameter of 20 nm, an ideal size for MRI and MPI detection as well as for hyperthermia-based therapies. The dendrimer coating significantly enhances the biocompatibility of these nanoparticles, reducing toxicity while enabling efficient and long-term internalization across various cell types.

Superbranche's nanoparticles have already been successfully tested on iPSCs, extracellular vesicles (EVs), and numerous other cell models, demonstrating high labeling efficiency and stability without compromising cell viability or function. This positions Superbranche's technology as a robust, scalable solution for precise cell tracking and therapeutic monitoring in clinical settings, paving the way for next-generation regenerative medicine, oncology and cell therapy applications.


Targets: Companies developing cell-based therapies



<https://www.superbranche.com/>

Delphine FELDER-FLESH
CEO & Founder

delphine.felder@superbranche.com





VECT-HORUS has developed a breakthrough technology platform “VECTrans®” based on the design and development of ligands that facilitate the targeted delivery of therapeutic or imaging agents into the brain and other organs.

By conjugating pharmaceutical agents to its ligands, also called vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules.

Based on its potential to target specific receptors, notably those that are found at high levels in some pathological tissues, VECT-HORUS is also targeting cancers (pancreatic, adrenal cancer, glioblastoma, etc.), where there is a high unmet medical need and other organs including skeletal and cardiac muscle.

Business Model

Vect-Horus’ business model is based on partnering with pharma and biotech companies to vectorize their therapeutic molecules which have not demonstrated expected effects due to e.g. limited brain uptake. Following the proof-of concept studies, Vect-Horus’ strategy is to out-license its vectors to the partner, which will further conduct the drug development process. The licensing agreements generate revenues that fund Vect-Horus’ technology and its development programs.

Targets: Pharma/Biotech, companies developing therapeutic molecules that need to deliver their molecule to the central nervous system or to pathological tissues



<https://www.vect-horus.com/>

Faustine VELASCO RAMEL
Senior Business Developer

faustine.velasco@vect-horus.com

Two major licensing agreements signed in 2023

A co-development & licensing agreement with RadioMedix for the diagnostic and therapy of glioblastoma and other cancers. The agent is currently in early Phase 1

More than a dozen of R&D collaborations with world-class pharmaceutical companies, which are global specialists in their applications. These have already resulted in multiple licensing and option agreements





ALPX, a leading French CRO and a EMBL spin-off, specializes in transparent structural biology services for biotech and pharma companies. We deliver high-quality, accelerated structural insights, enabling our partners to focus on optimizing their small molecule and biologic projects into promising lead candidates.

With our automated protein crystallography and Cryo-EM platforms, we provide a one-stop-shop solution for all structural biology needs.

Services:

All our services include access to fully automated, remote-controlled protein-to-structure pipelines based on the innovative technologies CrystalDirect™ and CRIMS developed at EMBL.



Your one-stop solution for fast structure determination and expert screening

Targets: Pharma, mid-size biotech, et small biotech with funding



<https://www.alpx-services.com/>

Alexandre DIAS Head of Business Development

dias@alpx-services.com



Automated
Crystallization Platform



Data Collection and
Processing



Membrane Protein
Crystallography



Online
Crystallography




Structure Solution
Refinement and Analysis



Compound and
Fragment Screening

Cryo-EM 





Banook Banook is a global provider of centralized services for clinical trials, offering solutions for Cardiac Safety, Central Imaging, Clinical Outcome Assessments (eCOA/ePRO) and Endpoint Adjudication. With over 25 years of experience, Banook supports pharmaceutical, biotech, and medical device companies in the design and execution of clinical studies from early to late phases.

Headquartered in France and operating internationally, Banook combines scientific expertise, technological innovation, and regulatory compliance to deliver high-quality data to help accelerate the development of safe and effective therapies.

25+

Years of experience

11K+

Sites

2 250+

Trials

120+500

Collaborators & scientific experts

Targets: Clinical Research Organization, Laboratoires pharmaceutiques

Alexandre DURAND-SALMON
CEO

alexandre.durand-salmon@banookgroup.com

SERVICES OVERVIEW



Cardiac safety




Central imaging



Endpoint adjudication



eCOA/ePRO



<https://www.banook.com/>



ICARE Group stands out as a leader in international standardization and regulation. Our core mission is to expertly support industrial players in the healthcare sector, guiding them through regulatory complexities to ensure that every product or device reaches the market with the highest level of compliance and safety.

Our expertise spans a broad range of essential services to ensure excellence and compliance for your products:

- Biocompatibility and Toxicology: Rigorous assessment for safe use.
- Validation and Qualification: Certified processes ensuring proven performance.
- Microbiology and Contamination Control: Strict protocols guaranteeing flawless microbiological integrity.
- Quality and Regulatory Affairs: Continuous monitoring to uphold uncompromising compliance.
- Training and Consulting: Shared expertise for complete mastery.



Rely on the ICARE Group to confidently navigate the regulatory and standardization landscape of healthcare products.

Targets: Medical Device Manufacturers, Pharmaceutical Products Consultants or Regulatory Affairs Firms



<https://www.groupeicare.com/>

Severine ITIER
CEO

severine.itier@groupeicare.com

Vincent BERNUS
Commercial Director

vincent.bernus@groupeicare.com



4 sites on 2 continents
& a global reach



200 employees



6 500 sq. m including
3 400 sq. m of cleanrooms



+ 200 standard services





Unither Pharmaceutical, Global CDMO, Specialized in Ophthalmology

Unither Pharmaceuticals is a global CDMO born in France, with 30+ years of aseptic expertise and innovation in drug development and manufacturing. We have a strong focus on ophthalmology, offering accessible and sustainable health solutions using Blow-Fill-Seal (BFS) technology for sterile unit-dose and multi-dose formats—with or without preservatives.

Our development services support pharmaceutical and biotech companies from early stages through proof of concept, scale-up, and commercial production. We bring deep experience in biologics, small molecules, and novel formulations.

We actively invest in R&D to advance innovative, patient-centered molecules and delivery platforms. While ophthalmology remains our strategic focus, our sterile technologies also serve injectable, respiratory, nasal, and oral therapies.

With a global manufacturing network and flexible partnership models, we help clients deliver safe, effective, and compliant treatments that address patient needs and improve their lives.

Together, let's advance ophthalmic and sterile drug delivery.

Targets: Big pharma, mid-size biotech, small biotech with fundings



<https://www.unither-pharma.com/>

100+

Products sold
in countries

5 billion

Unit doses in 2024
World leader in
Blow-Fill-Seal

2300+

employees

4

continents

30+

years of experience

€522million

revenue

Natalia SERVOL

Director of the Ophthalmology Division

natalia.servol@unitehr-pharma.com

What makes us unique ?



Innovation-driven company

Development team
on each site



BFS worldwide leader

Large manufacturing
capacities and
competitive solutions



Scalable capacity for a permanent supply

Welcoming your
projects at anytime



Global network

Delivering products
on your local market
and worldwide

TYPES OF COLLABORATION



Contract Development & Manufacturing

for strategic outsourcing




Turnkey Products & Dossiers

for out-licensing



Co-Development

with our customers





OUR PRODUCT LIST



CDMO & SERVICES

Unither Pharmaceutical – Global CDMO, Specialized in Ophthalmology

Unither Pharmaceuticals is a global CDMO born in France, with 30+ years of aseptic expertise and innovation in drug development and manufacturing. We have a strong focus on ophthalmology, offering accessible and sustainable health solutions using Blow-Fill-Seal (BFS) technology for sterile unit-dose and multi-dose formats—with or without preservatives.

Our development services support pharmaceutical and biotech companies from early stages through proof of concept, scale-up, and commercial production. We bring deep experience in biologics, small molecules, and novel formulations.

We actively invest in R&D to advance innovative, patient-centered molecules and delivery platforms. While ophthalmology remains our strategic focus, our sterile technologies also serve injectable, respiratory, nasal, and oral therapies.

With a global manufacturing network and flexible partnership models, we help clients deliver safe, effective, and compliant treatments that address patient needs and improve their lives.

Together, let's advance ophthalmic and sterile drug delivery.

Targets: Big pharma, mid-size biotech, small biotech with fundings



<https://www.unither-pharma.com/>

Natalia SERVOL Director of the Ophthalmology Division

natalia.servol@unitehr-pharma.com

What makes us unique ?



Innovation-driven company

Development team on each site



BFS worldwide leader

Large manufacturing capacities and competitive solutions



Scalable capacity for a permanent supply

Welcoming your projects at anytime



Global network

Delivering products on your local market and worldwide

TYPES OF COLLABORATION



Contract Development & Manufacturing

for strategic outsourcing



Turnkey Products & Dossiers

for out-licensing




Co-Development

with our customers



NETRI is an Techbio industrial start-up whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology-related adverse events, dermo-cosmetics, neurological disorders and neurotoxicity.

Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format - NeuroFluidics™ MEA - which acts as a data generation hub for its digital signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, Organ-on-chip hardware, AI-trained software, digital libraries and methods.



Targets: Big Pharma




<https://netri.com/>

Thibault HONEGGER
CEO & Co-founder

thibault.honegger@netri.com

**ONE MEA PLATFORM
TO INNervATE
ALL 3D CULTURES**

DUALINK™ WELL MEA





Sounduct is a MedTech specializing in hearing loss solutions.

“Ossiclear” device restores hearing to deaf people thanks to its **non-invasive double-bone conduction technology** to bypass the tympanic membrane and to address directly the inner ear. This patented technology is **the only hearing solution utilizing both the tragus and the mastoid** bones for full auditory spectrum, especially in noise.

Sounduct device **shifts the paradigm** of deafness :

Hearing will no longer come through the ear.

- Addresses some unresolved pathologies
- Substitutes some implants
- Works on all deafness families (including sensorineural / presbycusis)
- Patented transducers
- In-house algorithm for transducers
- In-house manufacturing
- In-house Apps Dev
- Specific AI sound filtering
- Tech can be deployed in other medical applications or sectors

Targets : Electronics companies and potential customers or partners (hearing aid retail networks, importers...)

Olivier GAUTHIER
CEO

olivier@sounduct.com



<https://sounduct.com/en/>



Institut Curie, France's leading cancer center, combines a world-renowned research center with a state-of-the-art hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie operates across three sites (Paris, Saint-Cloud, and Orsay), bringing together more than 3,800 researchers, physicians, and healthcare professionals around its three core missions: care, research, and education.

Recognized with the Carnot label for the excellence of its collaborative research, Institut Curie offers industry partners tailor-made collaborative research programs, drawing on the combined expertise of its research and clinical teams, as well as its cutting-edge technology platforms. These partnerships aim to accelerate the development of innovative cancer solutions, from therapeutic target identification to clinical validation.

Furthermore, Institut Curie has a strong patent portfolio with many technologies available for licensing.

Targets: Companies specialized in the development of oncology-related products (drug development, instruments, diagnostic tools, software)

KEY FIGURES

3800
Employees

86
Research teams

400
Medical Doctors

53000
Patients

200
ongoing clinical trials

1111
Patents

32
spin-offs

Jérémie WEBER
Deputy Director, Technology Transfer Office

jeremie.weber@curie.fr





The **Institut Pasteur**, a non-profit foundation with recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research. In the pursuit of its mission to tackle diseases in France and throughout the world, the Institut Pasteur operates in four main areas: research, public health, training, and development of research applications. More than 3000 people work on its Paris campus.

The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology, with research focusing on the biology of living systems. The Institut Pasteur's outstanding research is facilitated by the development of a technological environment of the highest standard, with core facilities for nanoimaging (cryo-electron microscopy, cryo-electron tomography, etc.), computational biology and artificial intelligence.

To meet the major scientific and health challenges of the coming year, the Institut Pasteur has drawn up an ambitious strategic plan, called "Pasteur 2030", with 4 scientific priorities:

- Fighting Infectious Diseases and Antimicrobial Resistance
- Understanding the Impact of Climate Change and Environmental Transitions on Health and Diseases
- Studying the mechanisms underlying non-communicable diseases and inflammation
- Exploring physiology, response to infection and immune responses at key stages of life, from early development (mother-child dyad) to aging

Targets: biotech, medical/health (treatment, diagnosis, prevention; not only for human but also for animals, ecosystem, planetary), device, technology, material, chemical, environmental (water, air, soil) manufacturing (bio-production), AI/information/data, energy (green energy), social benefits (public health, epidemiology, science education and training, aging society)



<https://www.pasteur.fr/en>

Mai BAN

Business Development Manager


mai.ban@pasteur.fr



A worldwide network of more than 30 members on five continents



Key Figures 2024





LYONBIOPOLE

AUVERGNE-RHÔNE-ALPES 
THE HEALTH INNOVATION NETWORK

Lyonbiopole is the health competitiveness cluster of the Auvergne-Rhône-Alpes region in France.

AT THE HEART OF A VIBRANT INNOVATION HUB

Located in Auvergne-Rhône-Alpes, the #1 region in France for:

- Health manufacturing
- Bioproduction
- Research & Development

With 900 innovative players & 150 industrial facilities

LYONBIOPOLE IS GATHERING 250 MEMBERS

- 208 innovative SMEs and start-ups
- 19 large companies
- 23 research centers and university hospitals

OUR MISSION

As a Health Competitiveness Cluster, our goal is to accelerate healthcare innovation through:

- Federating the regional network of scientific, technological and medical innovation
- Supporting members in their innovation, growth, internationalization and production projects
- Promoting the health ecosystem in France and internationally


Targets: biotech, pharma, diagnostics and medical technology companies with an interest in the French healthcare ecosystem and seeking to explore collaboration opportunities with French firms for co-development or in-licensing

Simon GUDIN

Head of International Affairs

simon.gudin@lyonbiopole.com

STRATEGIC AREA OF ACTIVITY



| APPLICATION MARKETS | TECHNOLOGIES | PATIENT JOURNEY



<https://lyonbiopole.com/en>

OUR PARTNER

ENOSIS SANTÉ THE FRENCH HEALTHTECH CLUSTER ALLIANCE

The Enosis Santé association was created in 2022 by 4 French healthcare clusters: BioValley France, Eurobiomed, Lyonbiopole Auvergne-Rhône-Alpes and Medicen Paris Region.

Through increased inter-cluster synergies, Enosis Santé aims to boost each cluster's capacity to accelerate the development of healthtech innovation, support innovative companies and reinforce France's leadership in healthcare.

Thanks to its close links with regional health innovation stakeholders, who are members of each cluster, and its involvement with the French government, Enosis Santé combines regional initiatives with the structuring of national strategic sectors.

+1430

Public and private
stakeholders

1200

Innovative companies

+400

R&D projects supported

€1,8 billion

raised by companies
from the 4 clusters in
one year

Enosis
santé

BIOVALLEY
france
l'innovation santé

EUROBIOMED

LYONBIOPOLE
AUVERGNE-RHÔNE-ALPES
THE HEALTH INNOVATION NETWORK

MEDICEN
PARIS
REGION



YOUR CONTACT



JAPON – Tokyo

Nicolas SESTIER

Directeur Adjoint
nicolas.sestier@businessfrance.fr



JAPON – Tokyo

Tomomi SHINADA

Chargée de développement
tomomi.shinada@businessfrance.fr



JAPON – Tokyo

Mikako SHIINA

Chargée d'affaire export
mikako.shiina@businessfrance.fr



FRANCE – Paris

Xinyi CAO

Cheffe de projet santé
xinyi.cao@businessfrance.fr

PARTNERS



Creators of business opportunities, throughout the world

As a public consulting firm, we work to support the international development of the French economy.

Convinced that the right meeting can change everything, we provide entrepreneurs with our expertise and the power of our network in France and around the world.

Our teams open new markets to French businesses, contributing to the economic attractiveness of France in the eyes of foreign investors with one aim: to generate activity and jobs.

We work to:

- Support the international development of French businesses established in France, over the long term, particularly mid-size companies and growing SMEs.
- Promote the sectors of French excellence and the sectors of the future, supporting competitiveness and innovation.
- Support the international development of French businesses and young talent by developing the VIE International Internship Program.
- Court and attract foreign investments to France that create value and jobs, and welcome and support international talent.
- Promote the economic image of France, its businesses and its regions.

For more information, visit: <https://www.businessfrance.fr/en>

